首页> 美国卫生研究院文献>Scientia Pharmaceutica >Antimycobacterial Activities of N-Substituted-Glycinyl 1H-123-Triazolyl Oxazolidinones and Analytical Method Development and Validation for a Representative Compound
【2h】

Antimycobacterial Activities of N-Substituted-Glycinyl 1H-123-Triazolyl Oxazolidinones and Analytical Method Development and Validation for a Representative Compound

机译:N-取代的甘氨酰1H-123-三唑基恶唑烷酮的抗分枝杆菌活性及代表性化合物的分析方法开发和验证

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Twelve N-substituted-glycinyl triazolyl oxazolidinone derivatives were screened for antimycobacterial activity against susceptible (Mycobacterium tuberculosis (Mtb) H37Rv) and resistant (isoniazid (INH)-resistant Mtb (SRI 1369), rifampin (RMP)-resistant Mtb (SRI 1367), and ofloxacin (OFX)-resistant Mtb (SRI 4000)) Mtb strains. Most of the compounds showed moderate to strong antimycobacterial activity against all strains tested, with minimum inhibitory concentration (MIC) value ranges of 0.5–11.5, 0.056–11.6, 0.11–5.8, and 0.03–11.6 μM, and percent inhibition ranges of 41–79%, 51–72%, 50–75%, and 52–71% against Mtb H37Rv, INH-R, RMP-R, and OFX-R M. tuberculosis, respectively. The 3,5-dinitrobenzoyl and 5-nitrofuroyl derivatives demonstrated strong antimycobacterial activities with the N-(5-nitrofuroyl) derivatives (>PH-145 and >PH-189) being the most potent, with MIC value range of 0.3–0.6 μM against all strains tested. Compounds were not bactericidal, but showed intracellular (macrophage) antimycobacterial activity. A reliable validated analytical method was developed for a representative compound >PH-189 using Waters Acquity ultra High-Performance Liquid Chromatography (UHPLC) system with quaternary Solvent Manager (H-Class). A simple extraction method indicated that >PH-189 was stable in human plasma after 90 min at 37 °C with more than 90% successfully recovered. Moreover, stress stability studies were performed and degradants were identified by using UHPLC-ESI-QToF under acidic, basic, and oxidative simulated conditions.
机译:筛选了12种N-取代的亚甘氨酰三唑基恶唑烷酮衍生物对易感性(结核分枝杆菌(Mtb)H37Rv)和耐药性(对异烟肼(INH)耐药的Mtb(SRI 1369),对利福平(RMP)耐药的Mtb(SRI 1367)的抗分枝杆菌活性和耐氧氟沙星(OFX)的Mtb(SRI 4000))Mtb菌株。大多数化合物对所有测试菌株均表现出中等至强的抗分枝杆菌活性,最小抑菌浓度(MIC)值范围为0.5–11.5、0.056–11.6、0.11–5.8和0.03–11.6μM,抑菌百分比范围为41–针对Mtb H37Rv,INH-R,RMP-R和OFX-R结核分枝杆菌分别为79%,51-72%,50-75%和52-71%。 3,5-二硝基苯甲酰基和5-硝基糠酰基衍生物表现出较强的抗分枝杆菌活性,其中N-(5-硝基糠酰基)衍生物(> PH-145 和> PH-189 )为最有效,针对所有测试菌株的MIC值范围为0.3–0.6μM。化合物没有杀菌作用,但表现出细胞内(巨噬细胞)抗分枝杆菌活性。使用具有四级溶剂管理器(H-Class)的沃特世Acquity超高效液相色谱(UHPLC)系统,开发了一种可靠的经过验证的分析方法,用于代表性化合物> PH-189 。一种简单的提取方法表明,> PH-189 在人血浆中在37°C下90分钟后是稳定的,成功回收了90%以上。此外,进行了应力稳定性研究,并在酸性,碱性和氧化模拟条件下,使用UHPLC-ESI-QToF鉴定了降解物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号